NCT05024721View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis

PHASE3CompletedINTERVENTIONAL
Enrollment

326

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

March 7, 2022

Study Completion Date

March 7, 2022

Conditions
Gastritis
Interventions
DRUG

HIP2101

Test drug

DRUG

RLD2101

Reference drug

DRUG

HPP2101

Placebo drug

DRUG

HPP2102

Placebo drug

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT05024721 - Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis | Biotech Hunter | Biotech Hunter